Back to search
FDAFDA · Food and drugs·Recall number D-0782-2017

TESTOST CYP SESAME OIL 5ML MDV 100MG/ML INJ, Injection, 100mg/mL, Rx only, 5 mL Glass/Multiple Dose vial, Prepared by Key Compounding Pharmacy

Published May 24, 2017 · Recall initiated: April 18, 2017

Summary

FDA records drug Class II recall D-0782-2017, published May 24, 2017 and initiated April 18, 2017. Recalling firm: Key Pharmacy and Compounding Center; Status: Terminated; Reported quantity: 2 vials; Lot: Lot # t01-16-2017@9, Exp 4/17/2017; t01-19-2017@89, Exp 4/20/2017. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility: The firm is recalling sterile compounded drugs within expiry due to lack of assurance of sterility.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Key Pharmacy and Compounding Center
Distributor
Distributed nationwide in U.S.A., Australia and Canada.
Lot
Lot # t01-16-2017@9, Exp 4/17/2017; t01-19-2017@89, Exp 4/20/2017.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was TESTOST CYP SESAME OIL 5ML MDV 100MG/ML INJ, Injection, 100mg/mL, Rx only, 5 mL Glass/Multiple Dose vial, Prepared by Key Compounding Pharmacy recalled?

Yes. FDA published recall D-0782-2017 on May 24, 2017. Reported hazard: Lack of Assurance of Sterility: The firm is recalling sterile compounded drugs within expiry due to lack of assurance of sterility.

What should I do if I have this product?

Voluntary: Firm initiated · Letter